Enveric Biosciences (ENVB) Operating Leases (2019 - 2022)
Enveric Biosciences (ENVB) posted Operating Leases of $63820.0 for Q4 2022, up 546.54% sequentially from $9871.0 in Q2 2022, and down 7.32% YoY from $68861.0 in Q4 2021.
Enveric Biosciences (ENVB) Operating Leases (2019 - 2022) Analysis & Trends
Enveric Biosciences has reported Operating Leases for 4 years, with the latest figure at $63820.0 in Q4 2022.
- Quarterly Operating Leases fell 7.32% year-over-year to $63820.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $63820.0 (down 7.32% YoY) and the FY2022 annual result came in at $63820.0, down 7.32% from the prior year.
- Operating Leases climbed to $63820.0 in Q4 2022 per ENVB's latest filing, from $9871.0 in the prior quarter.
- Over five years, Operating Leases peaked at $886935.0 in Q3 2020 and troughed at $9871.0 in Q2 2022.
- A 4-year average of $264070.8 and a median of $169897.0 in 2019 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2020 and 2022: Operating Leases soared 346.77% in 2020, then dropped 7.32% in 2022.
- Over 4 years, Operating Leases stood at $169897.0 in 2019, then surged by 422.04% to $886935.0 in 2020, then plunged by 92.24% to $68861.0 in 2021, then fell by 7.32% to $63820.0 in 2022.
- According to Business Quant data, Operating Leases over the past three periods registered $63820.0, $9871.0, and $40117.0 for Q4 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 63,820.00 |
| Jun 30, 2022 | 9,871.00 |
| Mar 31, 2022 | 40,117.00 |
| Dec 31, 2021 | 68,861.00 |
| Sep 30, 2020 | 886,935.00 |
| Jun 30, 2020 | 708,237.00 |
| Dec 31, 2019 | 169,897.00 |
| Sep 30, 2019 | 198,522.00 |
| Jun 30, 2019 | 230,377.00 |